Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00125970 · ClinicalTrials.gov registry record · Phase 2
HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 480
- Enrollment target
NCT00125970: Completed Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00125970 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 480 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (261% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00125970, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 480 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety of and immune response to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
Interventions
- BIOLOGICAL VRC-HIVADV014-00-VP
- BIOLOGICAL VRC-HIVDNA016-00-VP
- BIOLOGICAL VRC-HIVDNA016-00-VP placebo
- BIOLOGICAL VRC-HIVADV014-00-VP placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 480 participants |
| Start Date | 2005-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00125970 record still lists
NCT00125970 is an interventional study that assigns participants to a tested intervention. The registered 480 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (261% higher).
The record links to 0 conditions, and to 4 interventions - of which VRC-HIVADV014-00-VP is the first listed.
NCT00125970 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00125970 about?
NCT00125970 is a clinical study titled "HVTN Protocol 204 - A Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA016-00-VP, Followed by a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Boost, VRCHIVADV014-00-VP, in HIV-1 Uninfected Adult Participants". The purpose of the study is to determine the safety of and immune response to a DNA HIV vaccine followed by an adenoviral vector HIV vaccine in HIV uninfected adults.
What is the current status of trial NCT00125970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 480 participants. The study started on 2005-09. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00125970?
The interventions under investigation include: VRC-HIVADV014-00-VP (BIOLOGICAL), VRC-HIVDNA016-00-VP (BIOLOGICAL), VRC-HIVDNA016-00-VP placebo (BIOLOGICAL), VRC-HIVADV014-00-VP placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT00125970?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00125970's enrollment target sits among peer trials
480 76th of 2000 higher than 1,924 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
- NCT04948060 · 480 participants · NA
Tribally Engaged Approaches to Lung Screening (TEALS)
- NCT05053230 · 480 participants · NA
A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia